The Scientist

» drug development and disease/medicine

Most Recent

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

The National Institutes of Health is hosting a two-day conference on how the virus affects infants and children. The take-home message so far: microcephaly is but one of many potential problems for Zika-exposed fetuses.

0 Comments

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.

0 Comments

image: Neonatal Gut Bacteria Might Promote Asthma

Neonatal Gut Bacteria Might Promote Asthma

By | September 12, 2016

Byproducts of gut microbes in some 1-month–old babies trigger inflammation that is linked to later asthma development, researchers find.

1 Comment

image: Designing In Vitro Models of the Blood-Brain Barrier

Designing In Vitro Models of the Blood-Brain Barrier

By | September 1, 2016

Choosing the right model, be it 3-D or 2-D, requires wading through varied cell sources, cell types, and cell culture conditions.

0 Comments

image: The Challenges of Rare-Disease Research

The Challenges of Rare-Disease Research

By | September 1, 2016

With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.

0 Comments

Popular Now

  1. Publishers’ Legal Action Advances Against Sci-Hub
  2. Decoding the Tripping Brain
  3. Metabolomics Data Under Scrutiny
    Daily News Metabolomics Data Under Scrutiny

    Out of 25,000 features originally detected by metabolic profiling of E. coli, fewer than 1,000 represent unique metabolites, a study finds.

  4. Do Microbes Trigger Alzheimer’s Disease?
AAAS